USE OF TH9507 IN HIV INFECTED INDIVIDUALS WITH EXCESS ABDOMINAL FAT

TH9507 在腹部脂肪过多的 HIV 感染者中的应用

• 批准号: 7374765
• 负责人: STEVEN K. GRINSPOON
• 金额: $ 2.47万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7374765
• 关键词: USE; TH9507; HIV; INFECTED; INDIVIDUALS

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. HIV lipodystrophy is characterized by excess visceral fat, dyslipidemia, and low growth hormone (GH) levels. TH9507 is a GH releasing factor that physiologically increases GH levels. A previous study of TH9507 resulted in decreases in visceral adipose tissue (VAT) and trunk fat, increases in lean body mass and lipid profile improvement, and was generally well-tolerated. This study is aimed at investigating the effects of TH9507 for 26 weeks and duration of these benefits. The primary outcome is reduction of VAT.

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。HIV脂肪营养不良的特点是内脏脂肪过多，血脂异常，生长激素（GH）水平低。TH9507是一种生长激素释放因子，可在生理上增加生长激素水平。先前对TH9507的研究结果表明，内脏脂肪组织（VAT）和躯干脂肪减少，瘦体重增加，脂质谱改善，并且通常耐受性良好。本研究旨在研究TH9507持续26周的效果和这些益处的持续时间。主要结果是降低增值税。